Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Patient Registries Prove Value As Drug Development Tools

This article was originally published in Scrip

Executive Summary

It's easy for pharmaceutical and biotechnology companies to get caught up in biomarkers and scientific clinical endpoints as the end goals in drug development, but a novel, practical approach is gaining momentum: asking the patient what they need or want from new medicines.

Advertisement

Related Content

Bioverativ Fills Gap In Pipeline With $400m True North Buy
Venture Funding Deals: ADC Therapeutics, Unity Biotech Raise $100m-Plus
VC Roundup: October Brings Several New Venture Funds, Including Third Rock’s Fourth
DMD Pipeline: After Sarepta’s First-Ever Approval, Are Combinations Next?

Topics

Advertisement
UsernamePublicRestriction

Register

SC064992

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel